Key facts

Invented name
Kevzara
Active Substance
sarilumab
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0114/2021
PIP number
EMEA-001045-PIP01-10-M02
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis)
Route(s) of administration
Subcutaneous use
Contact for public enquiries

Sanofi-Aventis Recherche & Développement

Tel. +33 169745695
E-mail: contact-us@sanofi.com

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date

Decision

P/0144/2021: EMA decision of 17 March 2021 on the acceptance of a modification of an agreed paediatric investigation plan for sarilumab (Kevzara) (EMEA-001045-PIP01-10-M02)

How useful do you find this page?